Market Overview

Booz Allen Hamilton: Barclays Looks Beyond Q1 Estimate Beat

Booz Allen Hamilton: Barclays Looks Beyond Q1 Estimate Beat

Barclays expressed being impressed with Booz Allen Hamilton Holding Corporation (NYSE: BAH) management's "palpable optimism" on broadening future growth potential following the first-quarter beat.

"Under the helm of CEO Rozanski, BAH appears to be shifting seamlessly into a new-age technology/capability-focused company, with a clear understanding of the dynamics of both the government and the high-growth commercial/international markets and with sizable already-won contracts just awaiting execution. This is the primary source of our unchanged constructive stance on the stock," analyst Carter Copeland wrote in a note.

Related Link: Booz Allen Hamilton Among "Best Positioned" In Cybersecurity, According To Jefferies

The analyst said the company's potential headcount increases over the course of the year should spur greater billable expenses in high-growth markets such as systems development, cyber security and data analytics, leading to peer-leading top-line and EBITDA growth.

Specifically, management implied that they had reached critical mass in a network of commercial partnerships, which enables the company to be closer to the flow of innovation and technology, critical for a cutting-edge consultancy.

Copeland, who has an Overweight rating and $32 price target on the stock, raised current year EPS estimate to $1.68 from $1.65.

At time of writing, shares of Booz Allen were down 0.57 percent to $31.21.

Full ratings data available on Benzinga Pro.

Do you have ideas for articles/interviews you'd like to see more of on Benzinga? Please email with your best article ideas. One person will be randomly selected to win a $20 Amazon gift card!

Latest Ratings for BAH

Sep 2019Initiates Coverage OnEqual-Weight
Aug 2019MaintainsOverweight
Jul 2019MaintainsNeutral

View More Analyst Ratings for BAH
View the Latest Analyst Ratings

Posted-In: Analyst Color Earnings Long Ideas Price Target Reiteration Analyst Ratings Tech Trading Ideas Best of Benzinga


Related Articles (BAH)

View Comments and Join the Discussion!

USDA Daily Cattle Slaughter; Live Cattle Futures Move Down

Adaptimmune Gets Access To Priority Medicines Regulatory Support For Its SPEAR T-cell Therapy